Satyarx Pharma Innovations Pvt Ltd. has disclosed novel bicyclic compounds acting as DNA repair protein RAD51 homolog 1 inhibitors reported to be useful for the treatment of cancer.

Biohaven Therapeutics Ltd. has described potassium voltage-gated channel subfamily KQT member 2/3 (KCNQ2/3) activators reported to be useful for the treatment of epilepsy, pain, dyskinesia, schizophrenia, anxiety disorders, stroke, Rett syndrome, substance abuse and dependence, among others.

Ennovabio (Zhejiang) Pharmaceuticals Co. Ltd. and Shanghai Ennova Biopharmaceutical Co. Ltd. have described 5-membered and 6-membered heterocyclic compounds acting as non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of cancer, viral infection, transplant rejection, cardiovascular and inflammatory disorders, and autoimmune, myeloproliferative and metabolic diseases.

Medshine Discovery Inc. has divulged hypoxia inducible factor 2α (HIF-2α; EPAS1) inhibitors reported to be useful for the treatment of cancer.

Lhotse Bio Inc. has identified lysophospholipid LPA1 receptor (LPAR1; EDG2) antagonists reported to be useful for the treatment of cancer, fibrosis, chronic obstructive pulmonary disease, multiple sclerosis, inflammatory disorders, SARS-CoV-2 infection (COVID-19), transplant rejection and osteoporosis, among others.

Viva Star Biosciences (Suzhou) Co. Ltd. has synthesized NLRP3 inflammasome inhibitors reported to be useful for the treatment of cryopyrin-associated periodic syndrome, multiple sclerosis, atherosclerosis, type 2 diabetes, osteoarthritis, cancer, Alzheimer’s disease and Parkinson’s disease.

Researchers from Kanaph Therapeutics Inc. and Korea Research Institute of Chemical Technology have disclosed prostanoid EP2 and/or EP4 receptor subtype dual antagonists reported to be useful for the treatment of cancer.

Researchers at Ontario Institute for Cancer Research and Sunnybrook Research Institute have described isoquinoline derivatives acting as apoptosis regulator BAX and/or BAK inhibitors reported to be useful for the treatment of neurodegenerative disorders.

Sichuan University has divulged metallo-β-lactamase (MBL; bacterial) inhibitors reported to be useful for the treatment of bacterial infections.

Insusense ApS has identified sortilin (NT3; Gp95) antagonists reported to be useful for the treatment of neurodegeneration, cancer, pain, diabetes, diabetic retinopathy, glaucoma, hearing loss and cardiovascular disorders, among others.